Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action

A. Barnett; S. Ding; C. Murray; M. Chamberlain; S. Plummer; T. R. J. Evans; I. MacPherson; D. Bissett; C. R. Elcombe; C. R. Wolf

doi:10.1016/S1359-6349(10)71828-0

Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action

A. Barnett, S. Ding, C. Murray, M. Chamberlain, S. Plummer, T. R. J. Evans, I. MacPherson, D. Bissett, C. R. Elcombe, C. R. Wolf

Research output: Contribution to journal › Book/Film/Article review › peer-review

Original language	English
Pages (from-to)	45-46
Number of pages	2
Journal	EJC Supplements
Volume	8
Issue number	7
DOIs	https://doi.org/10.1016/S1359-6349(10)71828-0
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1359-6349(10)71828-0

Cite this

Barnett, A., Ding, S., Murray, C., Chamberlain, M., Plummer, S., Evans, T. R. J., MacPherson, I., Bissett, D., Elcombe, C. R., & Wolf, C. R. (2010). Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 8(7), 45-46. https://doi.org/10.1016/S1359-6349(10)71828-0

@article{4f31139e1f714235bccae3230b84b2df,

title = "Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action",

author = "A. Barnett and S. Ding and C. Murray and M. Chamberlain and S. Plummer and Evans, {T. R. J.} and I. MacPherson and D. Bissett and Elcombe, {C. R.} and Wolf, {C. R.}",

year = "2010",

doi = "10.1016/S1359-6349(10)71828-0",

language = "English",

volume = "8",

pages = "45--46",

journal = "EJC Supplements",

issn = "1359-6349",

publisher = "Elsevier",

number = "7",

}

Barnett, A, Ding, S, Murray, C, Chamberlain, M, Plummer, S, Evans, TRJ, MacPherson, I, Bissett, D, Elcombe, CR & Wolf, CR 2010, 'Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action', EJC Supplements, vol. 8, no. 7, pp. 45-46. https://doi.org/10.1016/S1359-6349(10)71828-0

TY - JOUR

T1 - Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases

T2 - Human tumor xenograft efficacy and in vitro mode of action

AU - Barnett, A.

AU - Ding, S.

AU - Murray, C.

AU - Chamberlain, M.

AU - Plummer, S.

AU - Evans, T. R. J.

AU - MacPherson, I.

AU - Bissett, D.

AU - Elcombe, C. R.

AU - Wolf, C. R.

PY - 2010

Y1 - 2010

U2 - 10.1016/S1359-6349(10)71828-0

DO - 10.1016/S1359-6349(10)71828-0

M3 - Book/Film/Article review

SN - 1359-6349

VL - 8

SP - 45

EP - 46

JO - EJC Supplements

JF - EJC Supplements

IS - 7

ER -